title: Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy.
abstract: We assessed the therapeutic significance of systematic aortic and pelvic lymphadenectomy followed by adjuvant therapy in node-positive endometrial carcinoma. Among 173 stage I-III patients, 30 (17%) had positive nodes: ten in the pelvic region alone (group P) and 20 in the aortic region alone or in both regions (group A). The adjuvant therapy was administered as follows: subjects in group P received 50 Gy pelvic radiation, including three post-surgical T3 (pT3) patients who received either one or three cycles of cisplatin-based chemotherapy before radiation. Subjects in group A were given three cycles of chemotherapy followed by 50 Gy pelvic and 50 Gy extended field periaortic radiation using a four-field or conformational technique. Five-year survival was 95% for 143 patients with negative nodes and 84% for 30 patients with positive nodes (100% for group P and 75% for group A). In group A, 5-year survival was 38% for eight patients with both pT3 and histology other than endometrioid type G1, and 91% for the remaining 12 patients. Either way, both group P and group A patients had a better prognosis than previously reported. In summary, aortic and pelvic lymphadenectomy and subsequent chemotherapy and radiation therapy based on node status seem to improve the survival of endometrial cancer patients with positive nodes.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Onda
authors.forename: H
authors.initials: H
authors.lastname: Yoshikawa
authors.forename: K
authors.initials: K
authors.lastname: Mizutani
authors.forename: M
authors.initials: M
authors.lastname: Mishima
authors.forename: H
authors.initials: H
authors.lastname: Yokota
authors.forename: H
authors.initials: H
authors.lastname: Nagano
authors.forename: Y
authors.initials: Y
authors.lastname: Ozaki
authors.forename: A
authors.initials: A
authors.lastname: Murakami
authors.forename: K
authors.initials: K
authors.lastname: Ueda
authors.forename: Y
authors.initials: Y
authors.lastname: Taketani
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018196:Carcinoma, Adenosquamous / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D018269:Carcinoma, Endometrioid / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D003627:Data Interpretation, Statistical; D016889:Endometrial Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin